Why the study?
Adult patients with ccTGA, significant systemic tricuspid valve regurgitation, and systemic right ventricular dysfunction face prohibitive surgical risk.
Is the PASCAL transcatheter valve repair system feasible to treat tricuspid regurgitation in adult patients with ccTGA?
Is the PASCAL transcatheter valve repair system feasible to treat tricuspid regurgitation in adult patients with ccTGA?
The PASCAL transcatheter valve repair system is feasible for minimally invasive treatment of systemic tricuspid regurgitation in adult patients with ccTGA who are at prohibitive surgical risk.
Supports feasibility in high-risk ccTGA; leaves open prospective validation of safety and durability.
Patients with congenitally corrected transposition of the great arteries (ccTGA) with significant systemic tricuspid valve regurgitation and systemic right ventricular dysfunction have prohibitive surgical risk in adulthood. The PASCAL transcatheter valve repair system enables minimally invasive percutaneous tricuspid valve repair in the complex anatomy of patients with ccTGA. (Level of Difficulty: Intermediate.)
No takes yet. Share an insight, caveat, or question.
Luedike et al. (2021) studied this question.
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: